NEWS ALERT SIGNUP STAY IN TOUCH HOME OUR COMPANY PRODUCT PORTFOLIO INVESTORS PRESS RELEASES CAREERS CONTACT READ OUR LATEST NEWS Committed to addressing unmet medical needs through reinventing existing medications We are a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Welcome to Hyloris We apply our knowhow and technological innovations to existing pharmaceuticals to unlock their hidden potential and address important unmet medical needs. We have built a broad proprietary pipeline of complex value-added reformulated and repurposed products that have the potential to offer significant advantages over currently available medications. Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks. ABOUT US We bring added value to the healthcare system through reformulation and repurposing, with the goal to change therapy outcomes and dramatically improve the lives of patients around the globe. Our products + We have built a broad proprietary portfolio of value-added reformulated and repurposed product candidates by applying our knowhow and technological innovations to existing pharmaceuticals. LEARN MORE Our strategy + Committed to addressing underserved needs through innovation with the goal to become the leader in number of 505(b)(2) value-added medicines in development. LEARN MORE Investor relations + Faster innovation at a much lower cost and risk to drive continuous growth and create shareholders’ value. LEARN MORE Press releases + Here you will find our latest and archived press releases. LEARN MORE Hyloris Pharmaceuticals SA HQ: Boulevard Gustave Kleyer 17, 4000 Liège, Belgium T:+32 (0)4 346 02 07 E:contact@hyloris.com Quick links HOME INVESTORS OUR STRATEGY PRODUCT PORTFOLIO OUR COMPANY PRESS RELEASES CAREERS CONTACT News alert signup Stay updated on the latest developments at Hyloris. NEWS VIA EMAIL 2021 - Hyloris Pharmaceuticals SA - Design & Development by CLICK GDPR - Privacy Policy GDPR - Cookies Policy Terms of website use We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All